Canaccord Genuity Group Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Intellia Therapeutics (NASDAQ:NTLA) had its price objective cut by equities researchers at Canaccord Genuity Group from $54.00 to $48.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price indicates a potential upside of 243.59% from the stock’s previous close.

Several other equities analysts also recently commented on the company. Oppenheimer set a $27.00 target price on Intellia Therapeutics in a research report on Friday, November 7th. Brookline Capital Acquisition restated a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday. William Blair raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday. Evercore set a $8.00 price target on Intellia Therapeutics and gave the company an “in-line” rating in a report on Tuesday, November 11th. Finally, JonesTrading downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Ten research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $19.14.

Intellia Therapeutics Stock Performance

Shares of NTLA stock traded down $1.47 during mid-day trading on Tuesday, reaching $13.97. The company’s stock had a trading volume of 7,328,557 shares, compared to its average volume of 5,436,175. The firm’s 50-day moving average is $12.01 and its two-hundred day moving average is $13.08. The company has a market cap of $1.65 billion, a P/E ratio of -3.65 and a beta of 2.09. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16. The business had revenue of $23.02 million for the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.27) earnings per share. Sell-side analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Activity at Intellia Therapeutics

In other news, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. The trade was a 7.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the sale, the chief executive officer owned 1,013,339 shares in the company, valued at $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 53,051 shares of company stock worth $488,600. 3.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. increased its stake in Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after purchasing an additional 808 shares in the last quarter. CWM LLC lifted its holdings in Intellia Therapeutics by 4.7% during the third quarter. CWM LLC now owns 19,187 shares of the company’s stock worth $331,000 after acquiring an additional 856 shares in the last quarter. Comerica Bank grew its stake in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the period. Federated Hermes Inc. raised its position in shares of Intellia Therapeutics by 39.7% during the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after purchasing an additional 927 shares during the period. Finally, Cyndeo Wealth Partners LLC lifted its holdings in shares of Intellia Therapeutics by 9.3% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after purchasing an additional 995 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical hold on MAGNITUDE Phase 3 for nex‑z, clearing the way to resume a late‑stage heart disease gene therapy trial — a major regulatory milestone that reduces near‑term program risk and supports timelines for a key asset. Read More.
• Positive Sentiment: Company announced presentations of three‑year follow‑up data and patient‑focused research for lonvoguran (lonvo‑z) at AAAAI; longer‑term efficacy/safety signals from a one‑time 50 mg dose could materially de‑risk that HAE program if data are favorable. Read More.
• Positive Sentiment: Multiple brokerages raised ratings and price targets (examples: HC Wainwright to $30, Leerink to $29, Citizens Jmp to $28; William Blair upgraded to Outperform), which can attract buy interest and provide cover for investors to re‑enter the shares. Read More. — and see William Blair upgrade coverage Read More..
• Neutral Sentiment: Market attention from high‑profile investors: media reported Cathie Wood (ARK) made bargain purchases this week; inclusion of NTLA in such trades can boost liquidity and short‑term interest but is not a fundamental change. Read More.
• Neutral Sentiment: Additional analyst activity includes RBC, Wells Fargo and others adjusting ratings/targets (some modest), reflecting mixed views on near‑term upside vs. clinical execution risk. Read More.
• Negative Sentiment: Underlying financials remain loss‑making: recent quarters show negative EPS, large net‑loss margins and analyst forecasts of continued negative FY2026 EPS, which keeps NTLA a high‑beta, binary biotech play dependent on clinical/regulatory outcomes.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.